Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia

NCT06660368 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.

NCT NCT06660368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06660368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multicenter, Randomized, Open-Label, Phase II Study of Salvage BCL2i Plus CLAG-M in Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Phase
Phase 2
Overall status
Recruiting
Start date
November 26, 2024
Completion date
November 30, 2027
Enrollment
52 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute myeloid leukemia (aml)